Small Pharma Analyst
Growth, long/short equity, biotech, healthcare

Ligand Pharmaceuticals - Priced To Perfection Or More Room To Run?

Executive summary:

    85% compounded revenue growth rate over next 3 years, 5-fold through 2018, with earnings per share expected to double between 2014 and 2016.Future revenue derived primarily from royalties from multiple products - margins on royalties are 100%, providing substantial bottom line growth given a near steady cost basis.The large number of project...
Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
WITH SEEKING ALPHA PRO, INVESTORS CAN ALSO:
  • Access Top Ideas, chosen by Seeking Alpha’s editors
  • Filter long and short ideas by market cap and sector
  • Get Coverage of over 5,000 stocks, many of which have little or no coverage elsewhere
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO." Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else." Patrick Rice, Mainstay Capital Management
100% Satisfaction Guaranteed
You are protected by the Seeking Alpha Money Back Guarantee and will get a prompt refund on the unused portion of your subscription at any time, for any reason.